Legacy Capital Group California Inc. Purchases New Shares in Hims & Hers Health, Inc. (NYSE:HIMS)

Legacy Capital Group California Inc. acquired a new position in Hims & Hers Health, Inc. (NYSE:HIMS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 84,167 shares of the company’s stock, valued at approximately $1,699,000.

Several other large investors also recently made changes to their positions in the business. Belpointe Asset Management LLC lifted its position in Hims & Hers Health by 10.0% during the 4th quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after buying an additional 1,205 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Hims & Hers Health by 5.6% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,335 shares of the company’s stock worth $261,000 after purchasing an additional 1,561 shares in the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Swiss National Bank increased its holdings in shares of Hims & Hers Health by 0.7% in the first quarter. Swiss National Bank now owns 281,500 shares of the company’s stock valued at $4,355,000 after purchasing an additional 2,000 shares in the last quarter. Finally, ProShare Advisors LLC raised its position in Hims & Hers Health by 10.0% in the 1st quarter. ProShare Advisors LLC now owns 22,257 shares of the company’s stock worth $344,000 after purchasing an additional 2,023 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Insider Buying and Selling

In other Hims & Hers Health news, COO Melissa Baird sold 16,784 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.00, for a total value of $285,328.00. Following the transaction, the chief operating officer now owns 585,800 shares of the company’s stock, valued at $9,958,600. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, insider Soleil Boughton sold 2,334 shares of the company’s stock in a transaction dated Tuesday, August 6th. The stock was sold at an average price of $17.30, for a total transaction of $40,378.20. Following the completion of the transaction, the insider now directly owns 164,475 shares of the company’s stock, valued at $2,845,417.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Melissa Baird sold 16,784 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $17.00, for a total value of $285,328.00. Following the completion of the sale, the chief operating officer now directly owns 585,800 shares in the company, valued at approximately $9,958,600. The disclosure for this sale can be found here. In the last three months, insiders sold 969,018 shares of company stock valued at $19,260,875. 17.71% of the stock is owned by corporate insiders.

Hims & Hers Health Trading Down 0.1 %

Shares of HIMS stock traded down $0.02 on Tuesday, hitting $16.54. The stock had a trading volume of 6,506,404 shares, compared to its average volume of 7,871,473. Hims & Hers Health, Inc. has a twelve month low of $5.65 and a twelve month high of $25.74. The company has a fifty day moving average price of $20.37 and a two-hundred day moving average price of $16.36. The firm has a market cap of $3.55 billion, a P/E ratio of -1,654.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, August 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to analysts’ expectations of $302.43 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The company’s revenue was up 51.8% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.03) earnings per share. On average, analysts expect that Hims & Hers Health, Inc. will post 0.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the company. TD Cowen lifted their target price on Hims & Hers Health from $15.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 11th. Piper Sandler reissued a “neutral” rating and set a $18.00 price objective on shares of Hims & Hers Health in a report on Tuesday, August 6th. Bank of America raised their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Jefferies Financial Group boosted their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, June 27th. Finally, Deutsche Bank Aktiengesellschaft raised their price objective on shares of Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $20.00.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.